BIOMEDE Trial
The BIOMEDE trial did not meet its primary endpoint. The BIOMEDE trial generated mechanistic evidence that may inform future therapeutic strategies. The BIOMEDE trial is treated as a major reference point for targeted therapy selection in…
1 sources - 4 claims
The BIOMEDE trial did not meet its primary endpoint. The BIOMEDE trial generated mechanistic evidence that may inform future therapeutic strategies. The BIOMEDE trial is treated as a major reference point for targeted therapy selection in H3K27-altered DIPGs. The BIOMEDE trial is presented as evidence that adaptive trial designs can be useful in DIPG research.